Nektar Therapeutics (NKTR): What's the Story?

Share

Manufacturers Life Insur The holds 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 114,357 shares. American International Group Inc now holds 118,366 shares valued at $2,841,000. Ameriprise Financial Inc. boosted its stake in Nektar Therapeutics by 9.1% during the 2nd quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company's stock valued at $395,330,000 after acquiring an additional 185,933 shares in the last quarter. Arizona State Retirement System increased its position in Nektar Therapeutics by 1.0% in the 2nd quarter. Municipal Employees Retirement System of MI now owns 30,250 shares of the biopharmaceutical company's stock valued at $520,000 after buying an additional 490 shares during the last quarter. A stock that maintains a relatively stable price has low volatility.

Insider Trades for Nektar Therapeutics show that the latest trade was made on 7 Nov 2017 where Doberstein (Stephen K), the Officer completed a transaction type "Sell" in which 300000 shares were traded at a price of $30.09. The company's past year sales total was 37450. Hedge funds and other institutional investors own 85.85% of the company's stock. The stock had a trading volume of 979,040 shares. The company has market cap of $5.97 billion. Nektar Therapeutics has a 1 year low of $11.41 and a 1 year high of $33.67.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: "Nektar Therapeutics: Updates To Thesis" on November 08, 2017, also Prnewswire.com with their article: "Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017" published on November 07, 2017, Seekingalpha.com published: "Nektar Therapeutics: Encouraging Data Revealed At SITC" on November 13, 2017. For the past quarter, shares have performed 68.57%. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business had revenue of $36.30 million for the quarter, compared to analysts' expectations of $32.42 million. Breaking that down further, it has performed -63.38% for the week, -61.76% for the month, -64.86% over the last quarter, -80.60% for the past half-year and -88.60% for this a year ago. The business's revenue was down 39.4% on a year-over-year basis.

Justice League Movie Gets a Perfectly '80s VHS Intro
I hope we get to see Gordon be this badass Simmons is talking about fight in the streets and show he is no slouch. But do you recall, the most important Justice League member of all?

Among 2 analysts covering IRSA Inversiones (NYSE:IRS), 1 have Buy rating, 0 Sell and 1 Hold. Citadel Limited Co has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of United States and worldwide trademark and copyright laws.

WARNING: "Nektar Therapeutics Target of Unusually Large Options Trading (NKTR)" was originally posted by StockNewsTimes and is the property of of StockNewsTimes.

Several other equities research analysts also recently weighed in on the stock. The company has a consensus rating of "Buy" and an average price target of $28.64. Zacks Investment Research raised Nektar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, September 29th. Aegis Capital maintained the stock with "Buy" rating in Thursday, May 11 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned "Buy" rating by Jefferies on Wednesday, November 8. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company.

Sydney's new ferry named Ferry McFerryface
They certainly weren't expecting that they would have to name the new vessel something ludicrous like Ferry McFerryface . Three other ferries have been named after notable Australian doctors Victor Chang , Fred Hollows and Catherine Hamlin .

Lannett has an analyst consensus of Moderate Buy, with a price target consensus of $24.75. The firm experienced a fall in short interest from September 29, 2017 to October 13, 2017 of -1.29%. Following the sale, the chief executive officer now owns 122,908 shares in the company, valued at $1,705,963.04. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The value of the position overall is up by 22.1%. Following the sale, the senior vice president now directly owns 31,102 shares of the company's stock, valued at approximately $600,890.64. Insiders own 5.44% of the company's stock.

Nektar Therapeutics is a biopharmaceutical company.

Kremlin TV Network RT Registers As 'Foreign Agent' in US
Solodovnikov, also registered personally as a foreign agent, but he said he "respectfully disagrees that FARA should apply". The programs are "not aimed to primarily benefit any foreign government or political party", he added.

Share